The Chemopreventive Agent Development Research Group promotes and supports research on cancer preventive agent development, from preclinical studies to phase I clinical trials. The group’s projects aim to intercept the carcinogenic process by identifying and developing preventative agents with the potential to block, reverse, or delay the early stages of cancer. In addition, the group supports research on clinically translatable biomarkers that can be used to monitor tumor initiation and progression or assess efficacy of preventive interventions.

Read more About the Chemopreventive Agent Development Research Group.

Staff

Funding Opportunities

Active Grants

Clinical Trials

Publications

News

Cancer Prevention Clinical Trials Network (CP-CTNet)

Research Centers develop and conduct early phase clinical trials to assess the preventive potential of agents and interventions of varying classes.

More about the Cancer Prevention Clinical Trials Network (CP-CTNet)

PREVENT Cancer Preclinical Drug Development Program (PREVENT)

The peer-reviewed research pipeline supports new prevention interventions and biomarkers headed toward clinical trials.

Read more about the PREVENT Cancer Preclinical Drug Development Program (PREVENT)

Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia)

Major medical research centers conduct systematic early clinical development of promising preventive agents.

More about the Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia)

Think Tank on Aspirin and Non-Steroidal Anti-inflammatory Drugs (NSAIDs) in Cancer Prevention

Date(s) and Time(s): 9/30/2021 9:00 a.m. - 1:30 p.m. ET; 10/1/2021: 9:00 a.m. - 1:00 p.m. ET, View the DRAFT Agenda for this meeting. WebEx information will be provided soon; please check back at a later date. No registration is required to attend.

Vaccine to Prevent Hereditary Cancers Nears Human Trials

One of the first-ever vaccines for the prevention of colorectal and other cancers in patients at high genetic risk for these malignancies is expected to start its early phase safety and immunogenicity trial in the first quarter of 2022, according to investigators.